IL-33 was seen to augment the cell death of ST2L-positive low-metastatic cells, but not of the ST2L-negative high-metastatic cells, suggesting that IL-33 enhances lung cancer progression by selecting for more malignant cells in the tumor microenvironment. Here, IL33 is linked to lung cancer.